Rockwell Medical (NASDAQ:RMTI – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Risk & Volatility
Rockwell Medical has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
Earnings and Valuation
This table compares Rockwell Medical and Exagen”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rockwell Medical | $69.26 million | 0.48 | -$5.31 million | ($0.15) | -5.64 |
| Exagen | $66.57 million | 0.99 | -$19.95 million | ($0.92) | -2.98 |
Rockwell Medical has higher revenue and earnings than Exagen. Rockwell Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
23.3% of Rockwell Medical shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 1.9% of Rockwell Medical shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Rockwell Medical and Exagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rockwell Medical | -7.67% | -15.64% | -9.61% |
| Exagen | -29.97% | -105.03% | -30.10% |
Analyst Recommendations
This is a breakdown of recent ratings for Rockwell Medical and Exagen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rockwell Medical | 1 | 0 | 1 | 0 | 2.00 |
| Exagen | 1 | 0 | 9 | 0 | 2.80 |
Rockwell Medical currently has a consensus target price of $2.00, suggesting a potential upside of 136.49%. Exagen has a consensus target price of $9.38, suggesting a potential upside of 242.15%. Given Exagen’s stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Rockwell Medical.
Summary
Exagen beats Rockwell Medical on 7 of the 13 factors compared between the two stocks.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
